BR112016012862A2 - formulações para vacinas para neoplasia - Google Patents

formulações para vacinas para neoplasia

Info

Publication number
BR112016012862A2
BR112016012862A2 BR112016012862A BR112016012862A BR112016012862A2 BR 112016012862 A2 BR112016012862 A2 BR 112016012862A2 BR 112016012862 A BR112016012862 A BR 112016012862A BR 112016012862 A BR112016012862 A BR 112016012862A BR 112016012862 A2 BR112016012862 A2 BR 112016012862A2
Authority
BR
Brazil
Prior art keywords
vaccine formulations
neoplasia vaccine
neoplasia
vaccine
formulation
Prior art date
Application number
BR112016012862A
Other languages
English (en)
Inventor
F Fritsch Edward
Javeri Indu
Nellaiappan Kaliappanadar
Original Assignee
Broad Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Broad Inst Inc filed Critical Broad Inst Inc
Publication of BR112016012862A2 publication Critical patent/BR112016012862A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001191—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001192—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

a presente invenção refere-se a vacina para neoplasia ou formulação de composição imunogênica para o tratamento ou prevenção de neoplasia em um indivíduo.
BR112016012862A 2013-12-06 2014-12-05 formulações para vacinas para neoplasia BR112016012862A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361913172P 2013-12-06 2013-12-06
PCT/US2014/068893 WO2015085233A1 (en) 2013-12-06 2014-12-05 Formulations for neoplasia vaccines

Publications (1)

Publication Number Publication Date
BR112016012862A2 true BR112016012862A2 (pt) 2017-09-26

Family

ID=52273528

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016012862A BR112016012862A2 (pt) 2013-12-06 2014-12-05 formulações para vacinas para neoplasia

Country Status (12)

Country Link
US (2) US20160310584A1 (pt)
EP (2) EP3076992B1 (pt)
JP (3) JP6740127B2 (pt)
KR (1) KR102429859B1 (pt)
CN (1) CN106132432A (pt)
AU (2) AU2014360198B2 (pt)
BR (1) BR112016012862A2 (pt)
CA (1) CA2932798C (pt)
ES (1) ES2921531T3 (pt)
IL (1) IL246025B (pt)
NZ (1) NZ721105A (pt)
WO (1) WO2015085233A1 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
US20160310584A1 (en) * 2013-12-06 2016-10-27 The Broad Institute Inc. Formulations for neoplasia vaccines
KR20160101073A (ko) 2013-12-20 2016-08-24 더 브로드 인스티튜트, 인코퍼레이티드 신생항원 백신과의 병용 요법
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
US10993997B2 (en) 2014-12-19 2021-05-04 The Broad Institute, Inc. Methods for profiling the t cell repertoire
AU2016260540B2 (en) 2015-05-13 2021-01-07 Agenus Inc. Vaccines for treatment and prevention of cancer
MY190974A (en) 2015-05-20 2022-05-25 Massachusetts Gen Hospital Shared neoantigens
TW202241500A (zh) * 2015-06-09 2022-11-01 美商博德研究所有限公司 用於贅瘤疫苗之調配物及其製備方法
GB201516047D0 (en) 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
US20190015491A1 (en) * 2016-01-08 2019-01-17 Vaccibody As Neoepitope rna cancer vaccine
US20170224796A1 (en) 2016-02-05 2017-08-10 Xeme Biopharma Inc. Therapeutic Cancer Vaccine Containing Tumor-Associated Neoantigens and Immunostimulants in a Delivery System
JP2020500552A (ja) * 2016-11-23 2020-01-16 グリットストーン オンコロジー インコーポレイテッド 新生抗原のウイルスによる送達方法
EP3552126A1 (en) * 2016-12-09 2019-10-16 Regeneron Pharmaceuticals, Inc. Systems and methods for sequencing t cell receptors and uses thereof
WO2018140391A1 (en) 2017-01-24 2018-08-02 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
SG11201910101SA (en) 2017-05-08 2019-11-28 Gritstone Oncology Inc Alphavirus neoantigen vectors
SG11201912429RA (en) * 2017-06-21 2020-01-30 Transgene Sa Personalized vaccine
CN107630036A (zh) * 2017-10-16 2018-01-26 佛山科学技术学院 一种番鸭细小病毒vp1基因重组鸽痘病毒转移载体
US11793867B2 (en) 2017-12-18 2023-10-24 Biontech Us Inc. Neoantigens and uses thereof
CA3096909A1 (en) 2018-04-26 2019-10-31 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
JP7437385B2 (ja) * 2018-09-06 2024-02-22 バヴァリアン・ノルディック・アクティーゼルスカブ 保管が改善されたポックスウイルス組成物
KR20220016137A (ko) 2019-05-30 2022-02-08 그릿스톤 바이오, 인코포레이티드 변형된 아데노바이러스
WO2021041518A2 (en) * 2019-08-27 2021-03-04 Turnstone Biologics Corp. Methods for inducing an immune response against neoantigens
JP2023540851A (ja) * 2020-07-30 2023-09-27 エヴァクシオン・バイオテック・アクティエセルスカブ ネオペプチトープ含有ワクチン剤の製造方法
KR20230046313A (ko) 2020-08-06 2023-04-05 그릿스톤 바이오, 인코포레이티드 다중에피토프 백신 카세트
CA3200644A1 (en) * 2020-12-23 2022-06-30 Erik AGHAJANI Nucleic acid stabilizing solution for vaccines, therapy, diagnostics, storage, and transport
GB202104715D0 (en) 2021-04-01 2021-05-19 Achilles Therapeutics Uk Ltd Identification of clonal neoantigens and uses thereof
CN117321189A (zh) 2021-04-30 2023-12-29 泰根制药有限公司 淋巴细胞的单血管扩增
US20220383996A1 (en) * 2021-05-27 2022-12-01 Amazon Technologies, Inc. Assigning peptides to peptide groups for vaccine development

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6923973B1 (en) * 2001-02-22 2005-08-02 Board Of Regents, The University Of Texas System Peptide and DNA immunization against Coccidioides immitis infections
DE60329201D1 (de) * 2002-09-20 2009-10-22 Chugai Pharmaceutical Co Ltd Substituierte wt1-peptide
US7084247B2 (en) * 2004-03-11 2006-08-01 Peptimmune, Inc. Identification of self and non-self antigens implicated in autoimmune diseases
US20090142363A1 (en) * 2005-08-03 2009-06-04 Medical And Biological Laboratories, Co., Ltd. Cytotoxic t-cell epitope peptide and use thereof
US8793895B2 (en) * 2006-02-10 2014-08-05 Praxair Technology, Inc. Lyophilization system and method
CA2651796A1 (en) * 2006-02-27 2007-09-07 Arizona Board Of Regents For And On Behalf Of Arizona State University Identification and use of novopeptides for the treatment of cancer
US9283260B2 (en) * 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
EP2450371B1 (en) * 2007-01-30 2015-04-29 Epivax, Inc. Regulatory t cell epitopes, compositions and uses thereof
DK2131857T3 (en) * 2007-03-22 2015-09-14 Univ Colorado Regents A method of producing an immunologically active adjuvansbundet dried vaccine composition
WO2008147186A1 (en) * 2007-05-31 2008-12-04 Academisch Ziekenhuis Leiden H.O.D.N. Lumc P53 peptide vaccine
AU2008296733B2 (en) * 2007-08-08 2013-07-11 The Board Of Regents Of The University Of Texas System VEGFR-1/NRP-1 targeting peptides
US20100204118A1 (en) * 2007-09-11 2010-08-12 Dorian Bevec Use of grf-1 (1-29 ) and corticotropin-releasing factor as therapeutic agents
TR201802233T4 (tr) * 2007-10-25 2018-03-21 Toray Industries İmmün cevap indükleyiciler.
AR073853A1 (es) * 2008-10-17 2010-12-09 Genentech Inc Metodo de tratamiento. uso
TW201138782A (en) * 2010-04-26 2011-11-16 Besins Healthcare Lu Sarl Low-oil pharmaceutical emulsion compositions comprising progestogen
EP3699266A1 (en) * 2010-05-14 2020-08-26 The General Hospital Corporation Neoantigen specific cytotoxic t cells for use in treating cancer
CA2809362C (en) * 2010-08-24 2020-03-10 University Of Pittsburgh - Of The Commonwealth System Of Higher Educatn Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
DK2714071T3 (da) * 2011-05-24 2019-09-16 Biontech Rna Pharmaceuticals Gmbh Individualiserede vacciner mod cancer
WO2013133405A1 (ja) * 2012-03-09 2013-09-12 オンコセラピー・サイエンス株式会社 ペプチドを含む医薬組成物
AU2014251207B2 (en) * 2013-04-07 2019-06-13 Dana-Farber Cancer Institute, Inc. Compositions and methods for personalized neoplasia vaccines
US20160310584A1 (en) * 2013-12-06 2016-10-27 The Broad Institute Inc. Formulations for neoplasia vaccines

Also Published As

Publication number Publication date
CA2932798A1 (en) 2015-06-11
JP2019131568A (ja) 2019-08-08
AU2020230295A1 (en) 2020-10-01
KR20160096643A (ko) 2016-08-16
EP3076992A1 (en) 2016-10-12
WO2015085233A1 (en) 2015-06-11
CA2932798C (en) 2022-09-20
KR102429859B1 (ko) 2022-08-04
EP3076992B1 (en) 2022-04-06
NZ721105A (en) 2022-04-29
IL246025B (en) 2022-02-01
AU2014360198A1 (en) 2016-07-14
EP4052724A1 (en) 2022-09-07
JP6916231B2 (ja) 2021-08-11
JP6740127B2 (ja) 2020-08-12
US20160310584A1 (en) 2016-10-27
ES2921531T3 (es) 2022-08-29
JP7285279B2 (ja) 2023-06-01
US20200330571A1 (en) 2020-10-22
AU2020230295B2 (en) 2024-03-07
JP2021113218A (ja) 2021-08-05
CN106132432A (zh) 2016-11-16
AU2014360198B2 (en) 2020-06-18
JP2016540779A (ja) 2016-12-28
IL246025A0 (en) 2016-07-31

Similar Documents

Publication Publication Date Title
BR112016012862A2 (pt) formulações para vacinas para neoplasia
BR112016014410A2 (pt) terapia de combinação com vacina de neoantígeno
BR112018073384A2 (pt) polinucleotídeos moduladores
BR112018010089A2 (pt) composições compreendendo cepas bacterianas
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
BR112018010720A8 (pt) agonistas do receptor de apelina e métodos de uso
BR112017002053A2 (pt) composto de acordo com a fórmula (i), composição farmacêutica, e usos de um composto
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
ECSP18001613A (es) Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
NI201500140A (es) Compuestos y composiciones terapéuticos
TR201909447T4 (tr) Aramkol tuzları.
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
BR112017009265A2 (pt) apilimode para uso no tratamento do câncer colorretal
BR112014030720A8 (pt) composto, composição farmacêutica e usos de inibidores de fbx03
CL2017000587A1 (es) Derivados de tetrahidroquinolina como inhibidores de bromodominio
PH12015502747A1 (en) Novel compounds for the treatment of cancer
BR112017005272A2 (pt) uso de cisteamina no tratamento de infecções causadas por leveduras/bolores
MX368268B (es) Formulacion de atazanavir y cobicistat para el tratamiento del virus de inmunodeficiencia humana (vih).
NI201500176A (es) Derivados de prodroga de triazolpiridinas sustituidas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]